Sangamo Therapeutics, Inc. (0R1D.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Sangamo Therapeutics, Inc.
Address
501 Canal Blvd
Richmond, CA 94804
United States of America (the)
Phone
510 970 6000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
142
First IPO Date
November 07, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Alexander D. Macrae Ch.B MRCP | Chief Executive Officer, President & Director | 930,255 | 1963 |
| Scott Willoughby | Senior Vice President, Chief Legal Officer & Corporate Secretary | 569,651 | 1975 |
| Nathalie Dubois-Stringfellow | Senior Vice President & Chief Development Officer | 585,224 | 1962 |
| Gregory Davis | Head of Research & Technology | 0 | 1970 |
| Stephanie J. Seiler | Vice President and Head of Business Development & Alliance Management | 0 | N/A |
| Phillip Ramsey | Chief Technical Officer | 0 | N/A |
| Louise Wilkie | Head of Global Corporate Communications & Investor Relations | 0 | N/A |
| Nikunj Jain | Interim CFO and Principal Financial & Accounting Officer | 0 | 1980 |
| David Ojala | Scientist II - Discovery & Translational Research | 0 | N/A |
Description
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
